Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 6/20 | 0.35 |
| ▸ | NAMPT | P43490 | 5/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8445986 | 0.78 | LMNA (0.44) | TBXAS1 | |
| SCHEMBL9368125 | 0.69 | CYP19A1 (0.41) | NAMPTCYP19A1TBXAS1HSD11B1FFAR2 | |
| SCHEMBL9368177 | 0.65 | NAMPT (0.43) | NAMPTCYP19A1TBXAS1TAAR1 | |
| SCHEMBL9367836 | 0.64 | TERT (0.41) | NAMPTCYP19A1TBXAS1HSD11B1TAAR1 | |
| SCHEMBL7876980 | 0.64 | TAAR1 (0.45) | CYP19A1HSD11B1FFAR2TAAR1 | |
| SCHEMBL9021042 | 0.63 | TAAR1 (0.41) | NAMPTCYP19A1HSD11B1FFAR2TAAR1 | |
| SCHEMBL7571292 | 0.62 | ALDH1A1 (0.42) | SLC13A5TBXAS1 | |
| Citric Acid SCHEMBL8445980 | 0.62 | LMNA (0.54) | — | |
| SCHEMBL8780738 | 0.61 | NAMPT (0.71) | NAMPT | |
| SCHEMBL24020497 | 0.59 | MIF (0.66) | SLC13A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0618907-A1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | Knoll AG (DE) | 1994-10-12 | — | — | EP | disclosed |